Literature DB >> 23863867

The impact of lobular and ductal breast cancer histology on the metastatic behavior and long term survival of breast cancer patients.

T Korhonen1, T Kuukasjärvi, H Huhtala, E L Alarmo, K Holli, A Kallioniemi, L Pylkkänen.   

Abstract

The aim of the study was to evaluate the long-term survival of patients with invasive lobular carcinomas (ILC) and invasive ductal carcinomas (IDC) and the metastatic behavior of these two disease entities. Originally, all consecutive patients with pure lobular invasive breast cancers diagnosed between 1990 and 1999 in the area served by the Tampere University Hospital and their matched IDC controls were identified and re-evaluated histopathologically in this follow-up study, resulting in a total of 243 ILCs and 243 IDCs. Data on recurrences and survival were collected until the end of year 2009. Statistical analyses including Kaplan-Meier method, log-rank test, Fisher's exact test and Cox regression analysis were performed with the PASW Statistics 18.0 computer program. P-values of <0.05 were considered statistically significant. Within the mean follow-up time of 10.04 years, locoregional recurrences were significantly more common among the ILCs than IDCs (35 vs. 20, p = 0.04), but no differences in the total number of distant recurrences or bilaterality were observed. However, when the first distant recurrence sites were studied, ILC patients had significantly less lung metastases (p = 0.04), but more skin metastases (p = 0.04). During the whole follow-up period IDCs metastasized significantly more frequently to the lungs (p = 0.002), whereas gastrointestinal metastases were more common among ILCs (p = 0.02). Although the known favorable prognostic factors (hormone receptor positivity, low grade, low s-phase) were more common for the ILCs, the disease-free survival, the overall survival and the survival after recurrence did not differ between the groups. However, the Cox-regression model showed significantly worse survival for ILCs after adjusting for age, TNM-status, grade and ER-positivity (p = 0.004). In conclusion, ILC and IDC differ in respect for visceral metastases. Despite the known favorable prognostic factors and originally favorable survival, patients with lobular histology appear to have a worse survival in the multivariate analysis after a prolonged follow-up.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Biology; Breast cancer; Cox-regression analysis; Ductal; Lobular; Recurrence

Mesh:

Year:  2013        PMID: 23863867     DOI: 10.1016/j.breast.2013.06.001

Source DB:  PubMed          Journal:  Breast        ISSN: 0960-9776            Impact factor:   4.380


  21 in total

1.  Clinicopathological characteristics and survival outcomes of invasive lobular carcinoma in different races.

Authors:  Li-Yuan Yang; Li-Peng Yang; Biao Zhu
Journal:  Oncotarget       Date:  2017-07-19

2.  Distinct Pattern of Metastases in Patients with Invasive Lobular Carcinoma of the Breast.

Authors:  Aju Mathew; Padma S Rajagopal; Vipin Villgran; Gurprataap S Sandhu; Rachel C Jankowitz; Mini Jacob; Margaret Rosenzweig; Steffi Oesterreich; Adam Brufsky
Journal:  Geburtshilfe Frauenheilkd       Date:  2017-06-28       Impact factor: 2.915

Review 3.  Invasive lobular carcinoma: an understudied emergent subtype of breast cancer.

Authors:  Jason A Mouabbi; Amy Hassan; Bora Lim; Gabriel N Hortobagyi; Debasish Tripathy; Rachel M Layman
Journal:  Breast Cancer Res Treat       Date:  2022-03-26       Impact factor: 4.872

Review 4.  The potential application of organoids in breast cancer research and treatment.

Authors:  Nasim Ebrahimi; Alireza Nasr Esfahani; Setare Samizade; Atena Mansouri; Masoud Ghanaatian; Samaneh Adelian; Vida Shadman Manesh; Michael R Hamblin
Journal:  Hum Genet       Date:  2021-10-28       Impact factor: 4.132

5.  Invasive lobular carcinoma cell lines are characterized by unique estrogen-mediated gene expression patterns and altered tamoxifen response.

Authors:  Matthew J Sikora; Kristine L Cooper; Amir Bahreini; Soumya Luthra; Guoying Wang; Uma R Chandran; Nancy E Davidson; David J Dabbs; Alana L Welm; Steffi Oesterreich
Journal:  Cancer Res       Date:  2014-01-14       Impact factor: 12.701

6.  A Comparison of the Clinicopathological Features, Metastasis Sites and Survival Outcomes of Invasive Lobular, Invasive Ductal and Mixed Invasive Ductal and Lobular Breast Carcinoma.

Authors:  Nüvit Duraker; Semih Hot; Arzu Akan; Pınar Özay Nayır
Journal:  Eur J Breast Health       Date:  2020-01-01

7.  Tumor-infiltrating lymphocytes are associated with poor prognosis in invasive lobular breast carcinoma.

Authors:  Jean-Christophe Tille; André F Vieira; Caroline Saint-Martin; Lounes Djerroudi; Laëtitia Furhmann; Francois-Clement Bidard; Youlia Kirova; Anne Tardivon; Fabien Reyal; Matthieu Carton; Anne Vincent-Salomon
Journal:  Mod Pathol       Date:  2020-05-13       Impact factor: 7.842

8.  Loss of E-cadherin leads to Id2-dependent inhibition of cell cycle progression in metastatic lobular breast cancer.

Authors:  Max A K Rätze; Thijs Koorman; Thijmen Sijnesael; Blessing Bassey-Archibong; Robert van de Ven; Lotte Enserink; Daan Visser; Sridevi Jaksani; Ignacio Viciano; Elvira R M Bakker; François Richard; Andrew Tutt; Lynda O'Leary; Amanda Fitzpatrick; Pere Roca-Cusachs; Paul J van Diest; Christine Desmedt; Juliet M Daniel; Clare M Isacke; Patrick W B Derksen
Journal:  Oncogene       Date:  2022-04-18       Impact factor: 8.756

Review 9.  High frequency of lobular breast cancer in distant metastases to the orbit.

Authors:  Mieke Raap; Wiebke Antonopoulos; Maximilian Dämmrich; Henriette Christgen; Diana Steinmann; Florian Länger; Ulrich Lehmann; Hans Kreipe; Matthias Christgen
Journal:  Cancer Med       Date:  2014-10-30       Impact factor: 4.452

10.  The role of lipolysis stimulated lipoprotein receptor in breast cancer and directing breast cancer cell behavior.

Authors:  Denise K Reaves; Katerina D Fagan-Solis; Karen Dunphy; Shannon D Oliver; David W Scott; Jodie M Fleming
Journal:  PLoS One       Date:  2014-03-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.